SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Schrodinger, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$23.12+0.52 (+2.30%)

Close on Oct 19, 2026

Market cap: $1.75B
P/E (TTM): –
Dividend yield: –

Dividends

Schrodinger has not reported a dividend

No dividend per share appears in Schrodinger's annual filings since fiscal 2018.

Where these numbers come from

Parsed from the XBRL in Schrodinger's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SDGR.

Revenue growth8.9% · median 14.9%

Operating margin-59.2% · median 7.5%

Net margin-21.0% · median 16.2%

Company	Revenue	Growth
ARVN	$316.70M	-15.0%
LGND	$290.54M	+54.9%
PTGX	$281.99M	+34.8%
SDGR	$259.04M	+8.9%
MRVI	$208.78M	-5.0%
EVO	–	–

Company

Next earnings (est.): Nov 4, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 850
Held by institutions: 86.5%
Auditor: KPMG LLP
SEC CIK: 1490978

Advertisement
300 × 250